RT Journal Article
SR Electronic
T1 Recommendations for clinical interpretation of variants found in non-coding regions of the genome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.28.21267792
DO 10.1101/2021.12.28.21267792
A1 Ellingford, Jamie M
A1 Ahn, Joo Wook
A1 Bagnall, Richard D
A1 Baralle, Diana
A1 Barton, Stephanie
A1 Campbell, Chris
A1 Downes, Kate
A1 Ellard, Sian
A1 Duff-Farrier, Celia
A1 FitzPatrick, David R
A1 Ingles, Jodie
A1 Krishnan, Neesha
A1 Lord, Jenny
A1 Martin, Hilary C
A1 Newman, William G
A1 O’Donnell-Luria, Anne
A1 Ramsden, Simon C
A1 Rehm, Heidi L
A1 Richardson, Ebony
A1 Singer-Berk, Moriel
A1 Taylor, Jenny C
A1 Williams, Maggie
A1 Wood, Jordan C
A1 Wright, Caroline F
A1 Harrison, Steven M
A1 Whiffin, Nicola
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.28.21267792.abstract
AB Purpose The majority of clinical genetic testing focuses almost exclusively on regions of the genome that directly encode proteins. The important role of variants in non-coding regions in penetrant disease is, however, increasingly being demonstrated, and the use of whole genome sequencing in clinical diagnostic settings is rising across a large range of genetic disorders. Despite this, there is no existing guidance on how current guidelines designed primarily for variants in protein-coding regions should be adapted for variants identified in other genomic contexts.Methods We convened a panel of clinical and research scientists with wide-ranging expertise in clinical variant interpretation, with specific experience in variants within non-coding regions. This panel discussed and refined an initial draft of the guidelines which were then extensively tested and reviewed by external groups.Results We discuss considerations specifically for variants in non-coding regions of the genome. We outline how to define candidate regulatory elements, highlight examples of mechanisms through which non-coding region variants can lead to penetrant monogenic disease, and outline how existing guidelines can be adapted for these variants.Conclusion These recommendations aim to increase the number and range of non-coding region variants that can be clinically interpreted, which, together with a compatible phenotype, can lead to new diagnoses and catalyse the discovery of novel disease mechanisms.Competing Interest StatementAODL is a paid member of the Scientific Advisory Board of Congenica. SMH is a paid employee of Ambry Genetics.Funding StatementNW is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 220134/Z/20/Z) and by grant funding from The Rosetrees Trust (Grant Number H5R01320). JME is supported by a postdoctoral research fellowship from the Health Education England Genomics Education Programme (HEE GEP). DB and JL are supported by DBs NIHR Research Professorship (RP-2016-07-011). WGN is supported by the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007) and JCT is supported by the Oxford NIHR Biomedical Research Centre. DRF is supported by the MRC University Unit award to the University of Edinburgh for the MRC Human Genetics Unit and by the Wellcome Strategic Award: Transforming Genomic Medicine Initiative (200990/Z/16/Z). JI is supported by a National Health and Medical Research Council Career Development Fellowship (#1162929). AODL is supported by the National Human Genome Research Institute grant U01HG011755. The ClinGen SVI as well as SMH and HLR are supported by the National Human Genome Research Institute grant U24HG006834.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work used the Genomics England 100,000 Genomes Project dataset which was granted ethical approval from the national research ethics committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.